Inozyme Pharma Inc (INZY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2025 | 12-2024 | 09-2024 | 06-2024 | 03-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -28,039 | -102,024 | -74,950 | -50,380 | -23,347 |
| Depreciation Amortization | -509 | -4,297 | -3,932 | -3,314 | -1,934 |
| Accounts payable and accrued liabilities | 1,140 | 1,364 | 1,044 | 2,361 | 1,000 |
| Other Working Capital | -2,935 | 4,714 | -1,101 | 819 | -1,340 |
| Other Operating Activity | 1,194 | 8,336 | 6,220 | 2,323 | 1,088 |
| Operating Cash Flow | $-29,149 | $-91,907 | $-72,719 | $-48,191 | $-24,533 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 33,684 | 67,060 | 51,603 | 28,242 | 10,426 |
| PPE Investments | N/A | -62 | -45 | -32 | -32 |
| Investing Cash Flow | $33,684 | $66,998 | $51,558 | $28,210 | $10,394 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 228 | 11,398 | 11,140 | 617 | 159 |
| Financing Cash Flow | $228 | $11,398 | $11,140 | $617 | $159 |
| Exchange Rate Effect | 2 | 4 | 8 | 9 | 10 |
| Beginning Cash Position | 21,392 | 34,899 | 34,899 | 34,899 | 34,899 |
| End Cash Position | 26,157 | 21,392 | 24,886 | 15,544 | 20,929 |
| Net Cash Flow | $4,763 | $-13,507 | $-10,013 | $-19,355 | $-13,980 |
| Free Cash Flow | |||||
| Operating Cash Flow | -29,149 | -91,907 | -72,719 | -48,191 | -24,533 |
| Capital Expenditure | N/A | -62 | -45 | -32 | -32 |
| Free Cash Flow | -29,149 | -91,969 | -72,764 | -48,223 | -24,565 |